Marc Goodman analyst LEERINK

Currently, out of the existing stock ratings of Marc Goodman - 233 which are a Buy (71.47%), 88 which are a Hold (26.99%), 5 which are a Sell (1.53%)

Marc Goodman

Work Performance Price Targets & Ratings Chart

Analyst Marc Goodman works at LEERINK and is covering the Healthcare sector with 676 price targets and ratings displayed on 42 stocks. Previously, Marc Goodman worked at UBS.

Marc Goodman's average stock forecast success ratio is 61.85% with an average time for price targets to be met of 250.98 days.

Most recent stock forecast was given on NBIX, Neurocrine Biosciences at 24-Jul-2023.

Wall Street Analyst Marc Goodman

Analyst best performing recommendations are on SAGE (SAGE THERAPEUTICS).
The best stock recommendation documented was for SAGE (SAGE THERAPEUTICS) at 12/4/2019. The price target of $63 was fulfilled within 1 day with a profit of $86.21 (57.78%) receiving and performance score of 577.78.

Average potential price target upside

ABBV AbbVie ACAD ACADIA Pharmaceuticals AGN ALDX Aldeyra Therapeutics AXSM Axsome Therapeutics BHVN Biohaven Pharmaceutical Holding Company Ltd BMY BristolMyers Squibb Company GILD Gilead Sciences GMTX JAZZ Jazz Pharmaceuticals plc LLY Eli Lilly and Company MNK MRK Merck . MYL NBIX Neurocrine Biosciences PRGO Perrigo Company plc REGN Regeneron Pharmaceuticals SAGE Sage Therapeutics VRTX Vertex Pharmaceuticals ZGNX Zogenix ALKS Alkermes plc HZNP Horizon Therapeutics PublicCompany APTX Aptinyx AVDL Avadel Pharmaceuticals plc GRAY KRTX Karuna Therapeutics AMLX ELYM MRNS VTRS XENE Xenon Pharmaceuticals ITCI IntraCellular Therapies STSA Satsuma Pharmaceuticals BIIB Biogen ACIU ADMS Adamas Pharmaceuticals ENDP Endo International plc EOLS Evolus GWPH NEOS PFE Pfizer RLMD

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Buy

170

$16.87 (11.02%)

163

2 months ago

33/34 (97.06%)

$24.97 (28.96%)

433

Buy

182

$28.87 (18.85%)

181

2 months 17 days ago

6/15 (40%)

$28.98 (32.96%)

467

Buy

155

5 months 23 days ago

1/1 (100%)

$21 (15.67%)

90

Buy

172

$18.87 (12.32%)

166

6 months 27 days ago

23/24 (95.83%)

$22.65 (31.91%)

519

Hold

127

7 months 6 days ago

1/1 (100%)

$21.13 (19.96%)

240

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Marc Goodman is most bullish on?

Potential upside of $9.54 has been obtained for NBIX (NEUROCRINE BIOSCIENCES)

Which stock is Marc Goodman is most reserved on?

Potential downside of $8.11 has been obtained for BMY (BRISTOLMYERS SQUIBB COMPANY)

What Year was the first public recommendation made by Marc Goodman?

On 2009

To continue looking at which analysts cover the stock please register to the basic or advanced membership

How to use the chart